High-dose therapy/stem cell support: Comparison of mice and humans

International Journal of Cancer

Volumn 65, Issue 5, 1996, Pages 695-699

  Teicher, Beverly A ^a   Northey, David ^a   Yuan, Jia ^a   Frei III, Emil ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C;

EID: 0029879679     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960301)65:5<695::AID-IJC22>3.0.CO;2-5     Document Type: Article

References (28)

1. CHAO, N.J. and BLUME, K.G., Bone marrow transplantation part II - autologous. West. J. Med., 152, 46-51 (1990).
2. CRADDOCK, C.F., APPERLEY, J.F., WRIGHT, E.G., HEALY, L.E., BENNETT, C.A., EVANS, M., GRIMSLEY, P.G. and GORDON, M.Y., Circulating stem cells in mice treated with cyclophosphamide. Blood, 80, 264-269 (1992).
3. CROWN, J., WASSHERHEIT, C., HAKES, T., FENNELLY, D., REICH, L., MOORE, M. and SCHNEIDER, J., Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J. nat. Cancer Inst., 84, 1935-1936 (1992).
4. DAMIA, G., KOMSCHLIES, K.L., FUTAMI, H., BACK, T., GRUYS, M.E., LONGO, D.L., KELLER, J.R., RUSCETTI, F.W. and WILTROUT, R.H., Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities. Cancer Res., 52, 4082-4089 (1992).
5. GULATI, S., YAHALOW, J. and PORTLOCK, C., Autologous bone marrow transplantation. Curr. Prob. Cancer, 15, 5-56 (1991).
6. JOHNSON, C.S., Interleukin-1: therapeutic potential for solid tumors. Cancer Invest., 11, 600-608 (1993).
7. KEATING, A., Autologous bone marrow transplantation. In: J.O. Armitage and K.H. Antman (eds.), High-dose cancer therapy, pp. 162-181, Williams and Wilkins, Baltimore (1992).
8. KENNEDY, M.J., DAVID, J., PASSOS-COELHO, J., NOGA, S.J., HUELSKAMP, A.M., OHLY, K. and DAVIDSON, N.E., Administration of human recombinant granulocyte colony-stimulating factor (Filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res., 53, 5424-5428 (1993).
9. KNOX, S.J., FOWLER, S., MARQUEZ, C. and HOPPE, R.T. Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 28, 445-450 (1993).
10. KOENIGSDMANN, M., TOPP, M.S., THIEL, E. and BERDEL, W.E., Recombinant human granulocyte colony-stimulating factor (rhG-CSF) does not stimulate in vivo tumour growth of the human colon cancer cell line HTB 38 which is responsive in vitro. Int. J. Oncol., 3, 1057-1059 (1993).
11. LYNCH, D.H., RUBIN, A.S., MILLER, R.E. and WILLIAMS, D.E., Protective effects of recombinant human interleukin-la in doxorubicin-treated normal and tumor-bearing mice. Cancer Res., 53, 1565-1570 (1993).
12. MOLINEUX, G., POJDA, Z., HAMPSON, I.N., LORD, B.I. and DEXTER, T.M., Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 65, 2153-2158 (1990).
13. MOORE, M.A.S. and WARREN, D.J., Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc. nat. Acad. Sci. (Wash.), 84, 7134-7138 (1987).
14. MOREB, J., ZUCALI, J.R., GROSS, M.A. and WEINER, R.S., Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide. J Immunol. 142, 1937-1942 (1989).
15. NAPARSTEK, E., OHANA, M., GREENBERGER, J.S. and SLAVIN, S., Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngereic bone marrow transplantation in mice. Exp. Hematol., 21, 131-137 (1993).
16. NEBEN, S., MARCUS, K. and MAUCH, P., Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood, 81, 1960-1967 (1993).
17. NETA, R., DOUCHES, S. and OPPENHEIM, J.J., Interleukin 1 is a radioprotector. J. Immunol., 136, 2483-2485 (1986).
18. NETA, R., OPPENHEIM, J.J. and DOUCHES, S.D., Interdependence of the radioprotective effects of human recombinant interleukin 1α, rumor necrosis factor a. granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J. Immunol., 140, 108-111 (1988).
19. SCHABEL, P.M., GRISWOLD, D.P., CORBETT, T.H. and LASTER, W.R., Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol. Ther., 20, 282-305 (1983).
20. SCHABEL, F.M., GRISWOLD, D.P., LASTER, W.R., CORBETT, T.H. and LLOYD, H.H., Quantitative evaluation of anticancer agent activity in experimental animals. In: A.C. Sartorelli, W.A. Creasey and J.R. Bertino (eds.), Pharmacology therapy, pp. 411-435, Pergamon Press, Oxford (1977).
21. TEICHER, B.A., Preclinical models for high dose therapy. In: J.O. Armitage and K.H. Antman (eds.), High-dose cancer therapy: pharmacology, hematopoietins, stem cells, pp. 14-42, Williams and Wilkins, Baltimore (1992).
22. TEICHER, B.A., HERMAN, T.S., HOLDEN, S.A., WANG, Y., PFEFFER, M.R., CRAWFORD, J.M. and FREI III, E., Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247, 1457-1461 (1990a).
23. TEICHER, B.A., HOLDEN, S.A., CUCCHI, C.A., CATHCART, K.N.S., KORBUT, T.T., FLATOW, J.L. and FREI III, E., Combination of N,N′,N″-triethylenethiophosphormaide and cyclophosphamide in vitro and in vivo. Cancer Res , 48, 94-100 (1988).
24. TEICHER, B.A., HOLDEN, S.A., EDER, J.P., BRANN, T.W., JONES, S.M. and FREI III, E., Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res., 49, 5994-5998 (1989a).
25. TEICHER, B.A., HOLDEN, S.A., EDER, J.P., HERMAN, T.S., ANTMAN, K.H. and FREI III, E., Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin. Oncol., 17, 18-32 (1990b).
26. TEICHER, B.A., HOLDEN, S.A., JONES, S.M., EDER, J.P. and HERMAN, T.S., Influence of scheduling on two-drug combinations of alkylating agents in vivo Cancer Chemother. Pharmacol., 25, 161-166 (1989b).
27. TEICHER, B.A., WAXMAN, D.J., HOLDEN, S.A., WANG, Y., CLARKE, L., ALVAREZ SOTOMAYOR, E., JONES, S.M. and FREI III, E., Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N′,N″-triethylenethiophosphoramide. Cancer Res., 49, 4996-5001 (1989c).
28. WILLIAMS, S.F., Application of peripheral blood progenitors to dose-intensive therapy of breast cancer. Breast Cancer Res. Treat., 26, S25-S29 (1993).